Skip to main content
Premium Trial:

Request an Annual Quote

New Product Watch: Jun 14, 2011

Premium

Affymetrix this week launched the Human Genome U133+ PM Array Strip for use on its GeneAtlas Personal Microarray System.

The new array strip allows users to conduct expression profiling of four samples at a time using the GeneAtlas. Each array in the strip contains more than 500,000 probes for measurements of gene expression per sample and as many as 9 to 11 unique probes to interrogate every mRNA transcript, Affy said.

The strip contains the same content as the firm's GeneChip HT HG-U133+ PM Array Plate, which runs on its higher-throughput GeneTitan system, and is based on its cartridge-format GeneChip Human Genome U133 Plus 2.0 Array.


Molecular Devices has launched the GenePix SL50 Slide Loader and GenePix Pro 7.2 Software for use in its microarray workflow.

The SL50 Slide Loader is a modular, external slide handling and storage system that can be added to the firm's existing GenePix 4300A or 4400A scanners. It has automation capacity for up to 50 microarrays, the Sunnyvale, Calif.-based company said.

The new software takes advantage of Windows 7 64-bit computing performance and handles the "most demanding image analysis tasks," the company added.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.